NCT06722599View on ClinicalTrials.gov

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

RecruitingOBSERVATIONAL

Enrollment

171

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER